Updated Agenda
The 6th Annual Peptide Therapeutics Symposium
San Diego, October 21 - 22, 2010
San Diego Marriott La Jolla
4240 La Jolla Village Drive,
La Jolla, CA 92037
| Thursday, October 21st | |
| 4:00 p.m. – 7:00 p.m. 5:00 p.m. – 5.10 p.m. |
Registration Check-in Welcoming Remarks |
| 5:10 p.m. – 6.30 p.m. | Venture Capital Panel Discussion Attractive Financing Structures for Emerging Biotechnology Companies |
| Panel Moderator | Richard DiMarchi, Ph.D. , Symposium Chairman & Director, Peptide Therapeutics Foundation, Linda and Jack Gill Chair in Biomolecular Sciences & Professor of Chemistry, Indiana University |
| Panelists | John Diekman, Ph.D., Founder & Managing Partner, 5AM Ventures Shehan Dissanayake, PhD, CEO, Tavistock Life Sciences Malcolm Finlayson, Ph.D., Venture Partner, Hamilton Bioventures Pratik Shah, Ph.D., Venture Partner, Thomas McNerney & Partners |
| 6:30 p.m. – 8:00 p.m. | Opening Reception |
| Friday, October 22nd | |
| 7:30 a.m. – 12:00 p.m. 7:30 a.m. – 8:30 a.m. |
Registration Check-in Breakfast |
| 8:30 a.m. – 8:45 a.m. | Opening Remarks |
| 8:45 a.m. – 9:25 a.m. | Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago Chemical Synthesis in the Development of Protein Therapeutics |
| 9:25 a.m. – 10:05 a.m. | Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute Chemically Programmed Immunity: Making Peptides Drugs and More |
| 10:05 am. – 10:45 a.m. | Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford Burnham Medical Research Institute Tumor-penetrating Peptides in Targeted Tumor Treatment |
| 10:45 a.m. – 11:10 a.m. | Beverage Break |
| 11:10 a.m. – 11:50 a.m. | Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies Glioblastoma: Cancer Stem Cells and Reprogramming |
| 11:50 a.m. – 12:30 p.m. | Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California, Davis, Cancer Center From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy |
| 12:30 p.m. – 1:30 p.m. | Lunch |
| 1:30 p.m. – 2:00 p.m. | Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals |
| 2:00 p.m. – 2:30 p.m. | Richard Jones, M.D., Chief Medical Officer, Syntaxin Early Clinical Development of Novel Biologics: A Comprehensive Overview |
| 2:30 p.m. – 3:00 p.m. | Richard Ross, M.D., Chief Scientific Officer and Director, Asterion Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals |
| 3:00 p.m. – 3:30 p.m. | Beverage Break |
| 3:30 p.m. – 4:00 p.m. | Hans-Peter Gerber, Ph.D., Senior Director Pfizer Antibody Drug Conjugates: Current and Future Developments |
| 4:00 p.m. – 4:30 p.m. | Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy |
| 4:30 p.m. – 5:00 p.m. | Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc. New Horizons in Protein Medicinal Chemistry Enabled with anExpanded Genetic Code |
| 5:00p.m. – 5:15 p.m. | Closing Remarks |
| 5:15 p.m. – 7:00 p.m. | Networking Reception |
Please visit our website to register for the meeting www.peptidetherapeutics.org.
Sincerely,
Program Committee
Peptide Therapeutics Foundation
If you would like to become a sponsor of this year’s Symposium please contact Adrienne Day at 858-657-1511.
To unsubscribe to future email notifications from the Peptide Therapeutic Foundation please email adrienne.day@peptidetherapeutics.org and include “unsubscribe” in the subject line.